Calculus Capital

Calculus Capital is a UK-based growth-stage investor and EIS/VCT-tax-efficient fund manager backing British SMEs across technology, healthcare, and consumer. The firm’s structure — with fund vehicles tied to the UK’s Enterprise Investment Scheme and Venture Capital Trust regimes — gives them a tax-driven LP base and a preference for British-incorporated companies that fit those regulatory criteria. Healthcare exposure is real and recurring, with deals across diagnostics, devices, digital health, and life sciences services. For healthcare AI founders, Calculus is the right partner if you are a UK-incorporated company at Series A or B, with revenue and a credible profitability path, looking for capital that comes with EIS/VCT-relevant structuring. Check sizes are plausibly GBP 1M to 5M per deal, with capacity to syndicate larger rounds across their VCT and EIS vehicles. Stage focus is later seed through Series B. Founders who should approach: UK healthcare AI businesses with traction, particularly those serving NHS trusts, private payers, or UK employers, where the EIS/VCT structuring is genuinely useful and the team is comfortable with the additional tax-compliance overhead. Founders who should not approach: US-incorporated companies, pre-revenue science plays, and teams that find the EIS/VCT compliance and reporting burden disproportionate to the capital. Entry path is warm introduction through UK corporate finance advisors, accountants, or portfolio CEOs. Their website and LinkedIn page provide direct contact for inbound submissions. Be prepared to discuss EIS/VCT eligibility — including qualifying trade tests and gross asset thresholds — early in the conversation, since the structural fit gates the financial decision.